Cardio Diagnostics Holdings Net Income
| CDIO Stock | USD 1.32 0.05 3.65% |
As of the 12th of February 2026, Cardio Diagnostics shows the Mean Deviation of 5.58, risk adjusted performance of (0.12), and Standard Deviation of 7.84. Cardio Diagnostics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Cardio Diagnostics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 3.7541 | Revenue | Earnings Share (11.91) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -7.5 M | -7.9 M | |
| Net Loss | -558.4 K | -586.3 K | |
| Net Loss | -7.5 M | -7.2 M | |
| Net Loss | (0.36) | (0.38) |
Cardio | Net Income | Build AI portfolio with Cardio Stock |
Evaluating Cardio Diagnostics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Cardio Diagnostics Holdings's fundamental strength.
Latest Cardio Diagnostics' Net Income Growth Pattern
Below is the plot of the Net Income of Cardio Diagnostics Holdings over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Cardio Diagnostics financial statement analysis. It represents the amount of money remaining after all of Cardio Diagnostics Holdings operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Cardio Diagnostics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cardio Diagnostics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (8.38 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Cardio Net Income Regression Statistics
| Arithmetic Mean | (2,553,617) | |
| Coefficient Of Variation | (125.39) | |
| Mean Deviation | 2,748,959 | |
| Median | (605,164) | |
| Standard Deviation | 3,201,975 | |
| Sample Variance | 10.3T | |
| Range | 7.8M | |
| R-Value | (0.78) | |
| Mean Square Error | 4.2T | |
| R-Squared | 0.61 | |
| Significance | 0.0002 | |
| Slope | (497,251) | |
| Total Sum of Squares | 164T |
Cardio Net Income History
Other Fundumenentals of Cardio Diagnostics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Cardio Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Cardio Diagnostics is extremely important. It helps to project a fair market value of Cardio Stock properly, considering its historical fundamentals such as Net Income. Since Cardio Diagnostics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cardio Diagnostics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cardio Diagnostics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Cardio diversify its offerings? Factors like these will boost the valuation of Cardio Diagnostics. Projected growth potential of Cardio fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Cardio Diagnostics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (11.91) | Revenue Per Share | Quarterly Revenue Growth (0.57) | Return On Assets | Return On Equity |
Cardio Diagnostics's market price often diverges from its book value, the accounting figure shown on Cardio's balance sheet. Smart investors calculate Cardio Diagnostics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Cardio Diagnostics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Cardio Diagnostics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cardio Diagnostics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Cardio Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cardio Diagnostics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cardio Diagnostics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cardio Diagnostics.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Cardio Diagnostics on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Cardio Diagnostics Holdings or generate 0.0% return on investment in Cardio Diagnostics over 90 days. Cardio Diagnostics is related to or competes with Addex Therapeutics, Brainstorm Cell, Neurosense Therapeutics, Matinas BioPharma, Creative Medical, Adial Pharmaceuticals, and Alaunos Therapeutics. Cardio Diagnostics Inc. develops and manufactures a genetic and epigenetic based test for prevention and detection of ca... More
Cardio Diagnostics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cardio Diagnostics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cardio Diagnostics Holdings upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.17) | |||
| Maximum Drawdown | 38.04 | |||
| Value At Risk | (13.93) | |||
| Potential Upside | 14.54 |
Cardio Diagnostics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cardio Diagnostics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cardio Diagnostics' standard deviation. In reality, there are many statistical measures that can use Cardio Diagnostics historical prices to predict the future Cardio Diagnostics' volatility.| Risk Adjusted Performance | (0.12) | |||
| Jensen Alpha | (1.63) | |||
| Total Risk Alpha | (2.20) | |||
| Treynor Ratio | (0.33) |
Cardio Diagnostics February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (0.32) | |||
| Mean Deviation | 5.58 | |||
| Coefficient Of Variation | (620.12) | |||
| Standard Deviation | 7.84 | |||
| Variance | 61.4 | |||
| Information Ratio | (0.17) | |||
| Jensen Alpha | (1.63) | |||
| Total Risk Alpha | (2.20) | |||
| Treynor Ratio | (0.33) | |||
| Maximum Drawdown | 38.04 | |||
| Value At Risk | (13.93) | |||
| Potential Upside | 14.54 | |||
| Skewness | 1.01 | |||
| Kurtosis | 2.12 |
Cardio Diagnostics Backtested Returns
Cardio Diagnostics secures Sharpe Ratio (or Efficiency) of -0.15, which signifies that the company had a -0.15 % return per unit of risk over the last 3 months. Cardio Diagnostics Holdings exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Cardio Diagnostics' Mean Deviation of 5.58, risk adjusted performance of (0.12), and Standard Deviation of 7.84 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 3.81, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cardio Diagnostics will likely underperform. At this point, Cardio Diagnostics has a negative expected return of -1.25%. Please make sure to confirm Cardio Diagnostics' potential upside, as well as the relationship between the daily balance of power and price action indicator , to decide if Cardio Diagnostics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.4 |
Poor reverse predictability
Cardio Diagnostics Holdings has poor reverse predictability. Overlapping area represents the amount of predictability between Cardio Diagnostics time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cardio Diagnostics price movement. The serial correlation of -0.4 indicates that just about 40.0% of current Cardio Diagnostics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.4 | |
| Spearman Rank Test | -0.34 | |
| Residual Average | 0.0 | |
| Price Variance | 0.36 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Cardio Diagnostics Holdings reported net income of (8.38 Million). This is 102.46% lower than that of the Biotechnology sector and 111.97% lower than that of the Health Care industry. The net income for all United States stocks is 101.47% higher than that of the company.
Cardio Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cardio Diagnostics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cardio Diagnostics could also be used in its relative valuation, which is a method of valuing Cardio Diagnostics by comparing valuation metrics of similar companies.Cardio Diagnostics is currently under evaluation in net income category among its peers.
Cardio Diagnostics Institutional Holders
Institutional Holdings refers to the ownership stake in Cardio Diagnostics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Cardio Diagnostics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cardio Diagnostics' value.| Shares | Sbi Securities Co Ltd | 2025-06-30 | 70.0 | Bank Of America Corp | 2025-06-30 | 15.0 | Srs Capital Advisors Inc | 2025-06-30 | 6.0 | Fmr Inc | 2025-06-30 | 3.0 | Citigroup Inc | 2025-03-31 | 0.0 | Millennium Management Llc | 2025-03-31 | 0.0 | Scientech Research Llc | 2025-03-31 | 0.0 | Endowment Wealth Management, Inc. | 2025-06-30 | 0.0 | Lpl Financial Corp | 2025-06-30 | 0.0 | Blackrock Inc | 2025-06-30 | 35.6 K | Geode Capital Management, Llc | 2025-06-30 | 13.4 K |
Cardio Fundamentals
| Return On Equity | -1.11 | ||||
| Return On Asset | -0.62 | ||||
| Operating Margin | (599.51) % | ||||
| Current Valuation | (3.44 M) | ||||
| Shares Outstanding | 1.83 M | ||||
| Shares Owned By Insiders | 6.79 % | ||||
| Shares Owned By Institutions | 6.35 % | ||||
| Number Of Shares Shorted | 144.49 K | ||||
| Price To Book | 0.30 X | ||||
| Price To Sales | 158.52 X | ||||
| Revenue | 34.89 K | ||||
| Gross Profit | 15.78 K | ||||
| EBITDA | (8.09 M) | ||||
| Net Income | (8.38 M) | ||||
| Cash And Equivalents | 9.66 M | ||||
| Cash Per Share | 5.08 X | ||||
| Total Debt | 969.86 K | ||||
| Current Ratio | 18.42 X | ||||
| Book Value Per Share | 4.61 X | ||||
| Cash Flow From Operations | (4.99 M) | ||||
| Short Ratio | 0.13 X | ||||
| Earnings Per Share | (11.91) X | ||||
| Target Price | 60.0 | ||||
| Number Of Employees | 13 | ||||
| Beta | 2.87 | ||||
| Market Capitalization | 2.5 M | ||||
| Total Asset | 10.62 M | ||||
| Retained Earnings | (22.75 M) | ||||
| Working Capital | 8.16 M | ||||
| Net Asset | 10.62 M |
About Cardio Diagnostics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cardio Diagnostics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cardio Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cardio Diagnostics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Cardio Diagnostics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cardio Diagnostics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardio Diagnostics will appreciate offsetting losses from the drop in the long position's value.Moving together with Cardio Stock
Moving against Cardio Stock
| 0.56 | DSGN | Design Therapeutics | PairCorr |
| 0.55 | ENGN | enGene Holdings Common | PairCorr |
| 0.51 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.43 | 63E | ONWARD MEDICAL BV | PairCorr |
The ability to find closely correlated positions to Cardio Diagnostics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cardio Diagnostics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cardio Diagnostics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cardio Diagnostics Holdings to buy it.
The correlation of Cardio Diagnostics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cardio Diagnostics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cardio Diagnostics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cardio Diagnostics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Will Biotechnology sector continue expanding? Could Cardio diversify its offerings? Factors like these will boost the valuation of Cardio Diagnostics. Projected growth potential of Cardio fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Cardio Diagnostics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (11.91) | Revenue Per Share | Quarterly Revenue Growth (0.57) | Return On Assets | Return On Equity |
Cardio Diagnostics's market price often diverges from its book value, the accounting figure shown on Cardio's balance sheet. Smart investors calculate Cardio Diagnostics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Cardio Diagnostics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Cardio Diagnostics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cardio Diagnostics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Cardio Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.